Abiopharma

🔍 Myers Kristin (Executive)

Company: Arcellx, Inc. (ACLX)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Sold 16,829 shares of Stock Option (right to buy) at $69.87 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2035-03-18 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,784 shares of Stock Option (right to buy) at $63.68 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2035-05-29 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.